Synlogic (NASDAQ:SYBX – Get Free Report) was upgraded by stock analysts at HC Wainwright from a “sell” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat.com reports.
Other research analysts have also issued reports about the stock. SVB Leerink reissued a “market perform” rating on shares of Synlogic in a research note on Friday, February 9th. Leerink Partnrs lowered shares of Synlogic from an “outperform” rating to a “market perform” rating in a research report on Friday, February 9th. Alliance Global Partners initiated coverage on shares of Synlogic in a research report on Monday, December 11th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Chardan Capital lowered shares of Synlogic from a “buy” rating to a “neutral” rating in a research report on Friday, February 9th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Synlogic presently has a consensus rating of “Hold” and a consensus target price of $65.00.
Read Our Latest Report on Synlogic
Synlogic Price Performance
Institutional Trading of Synlogic
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new stake in Synlogic in the first quarter valued at approximately $27,000. WINTON GROUP Ltd purchased a new stake in Synlogic in the third quarter valued at approximately $35,000. Citadel Advisors LLC acquired a new position in shares of Synlogic in the fourth quarter worth $42,000. Envestnet Asset Management Inc. grew its stake in shares of Synlogic by 273.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 78,671 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 57,604 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Synlogic by 333.6% in the fourth quarter. Millennium Management LLC now owns 95,434 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 73,422 shares in the last quarter. Hedge funds and other institutional investors own 47.18% of the company’s stock.
About Synlogic
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
Featured Stories
- Five stocks we like better than Synlogic
- What is the Hang Seng index?
- Google and Meta Circling the Market on a TikTok Ban Rally
- Insider Trades May Not Tell You What You Think
- Intuitive Machines: Charting a Course Among the Stars
- What Do S&P 500 Stocks Tell Investors About the Market?
- KB Home’s Stock Price Can Move Higher, Here’s Why
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.